Latest Health News
CROI 2026 Opens with Warning on HIV Research Funding Threats
The Conference on Retroviruses and Opportunistic Infections began with warnings that funding cuts and political interference threaten decades-old HIV research infrastructure. Progress toward HIV cure depends on sustained collaboration, with researchers advancing mRNA-based approaches and CRISPR technologies to target latent virus
.
PEPFAR Funding Freeze Disrupts Global HIV Services
A fundamental rupture in global HIV service delivery has occurred following US Administration funding and policy changes, with partner organizations receiving stop work orders. PEPFAR, which has saved over 25 million lives since 2003, faces severe disruption as the organization grapples with foreign assistance freezes
.
University of Rochester Awarded $22M for Aging Research Using HIV Drug
Researchers received up to $22 million in ARPA-H funding to test whether TPN-101, an antiviral drug originally developed for HIV, can suppress retrotransposon activity and reduce age-related inflammation. The study will enroll 200 healthy adults aged 60-65 for a 48-week clinical trial assessing impacts on mobility, cognition, and overall health
.
HIV Researcher Peter Staley Describes 2025 as 'Annus Horribilis' for Science
At CROI 2026, activist Peter Staley detailed unprecedented destruction to US science programs following the Trump administration's return, including targeted cuts affecting women and people of color in leadership roles. Despite challenges, he noted bipartisan pushback has resulted in increased NIH and NIAID funding
.
FDA Approves Multiple Breakthrough Therapies in February 2026
The FDA approved several significant medications including the first therapy for transplant-associated thrombotic microangiopathy, a MASP-2 inhibitor for patients undergoing stem cell transplants. Additional approvals included pembrolizumab for platinum-resistant ovarian cancer and therapies for thalassemia and multiple myeloma
.
Vaccines Advisory Committee to Discuss 2026-2027 Flu Season Vaccine Composition
The Vaccines and Related Biological Products Advisory Committee will meet on March 12, 2026, to recommend influenza virus vaccine strain composition for the upcoming 2026-2027 flu season. The meeting will be available via livestream
.
FDA Launches Safety Assessment of Food Preservative BHA
The FDA began evaluating butylated hydroxyanisole (BHA), a common food chemical preservative, on February 10, 2026, to determine its safety under current conditions of use. The post-market assessment includes a request for information on BHA's use and safety based on latest scientific findings
.
CBO Projects $245 Billion Savings from Skin Substitute Payment Changes
The Congressional Budget Office released estimates on February 11, 2026, indicating that recent skin substitute payment policy changes would reduce federal spending by approximately $245 billion over 10 years. The significant reductions raise concerns about effects on market viability, innovation, and patient access
.
Global Health Funding Opportunities and Prize Nominations Open
The Montrone-Seigel Prize in Biomedical Sciences now accepts nominations for outstanding investigators aged 52 or younger making breakthroughs in basic, clinical, or translational research. Multiple global health funding opportunities and conferences are available through the NIH Fogarty International Center
.
CDC Immunization Committee Meeting Postponed Due to Litigation
The CDC's Advisory Committee on Immunization Practices (ACIP) scheduled meeting for February 25-27, 2026, has been postponed due to ongoing litigation, with no new date announced.
Research Links Budget Cuts to PrEP Adherence Decline Globally
New research demonstrates that adherence to antiretroviral therapy and pre-exposure prophylaxis depends on steady funding through programs like PEPFAR and SNAP. Budget cuts threaten medication adherence both domestically and internationally
.
Johnson & Johnson Seeks FDA Approval for First Warm Autoimmune Hemolytic Anemia Treatment
Johnson & Johnson has submitted an FDA application for IMAAVY (nipocalimab-aahu) to become the first-ever FDA-approved treatment specifically for warm autoimmune hemolytic anemia (wAIHA).